Venus Remedies Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+10.3%1-day move

₹1160.00

prior close

₹1219.10

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.0+0.0+0.0+0.0+10.3+15.9+21.7+27.7+34.1+41.9+48.5+66.3+35.6—

Up moveDown movePending

AI summary

Venus Remedies Limited reported strong audited financial results for FY2025-26 (standalone). Revenue from operations grew 19.3% to Rs. 768.73 crore from Rs. 644.47 crore. Net profit surged 89% to Rs. 99.31 crore from Rs. 52.55 crore. EBITDA expanded significantly to Rs. 155.37 crore from Rs. 90.77 crore, with margin improving from ~14% to ~20%. EPS (basic) stood at Rs. 74.29 versus Rs. 39.32. Consolidated net profit was Rs. 102.78 crore (up 127%). The Board recommended a final dividend of Rs. 10 per share (100%). Auditors issued an unmodified (clean) opinion. The company has a subsidiary in Germany (Venus Pharma GmbH) and step-down subsidiary in Hungary (Venus Pharma Kft).

Likely market impact

Strong financial performance with near doubling of profits and significant margin expansion indicates operational efficiency gains. The company appears fundamentally strong with cash flow from operations at Rs. 151.09 crore (standalone).